A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
Top Cited Papers
- 8 May 2025
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (18) , 1801-1812
Abstract
Automated insulin delivery (AID) systems have been shown to be beneficial for patients with type 1 diabetes, but data are needed from randomized, controlled trials regarding their role in the management of insulin-treated type 2 diabetes. In this 13-week, multicenter trial, adults with insulin-treated type 2 diabetes were randomly assigned in a 2:1 ratio to receive AID or to continue their pretrial insulin-delivery method (control group); both groups received continuous glucose monitoring (CGM). The primary outcome was the glycated hemoglobin level at 13 weeks. A total of 319 patients underwent randomization. Glycated hemoglobin levels decreased by 0.9 percentage points (from 8.2±1.4% at baseline to 7.3±0.9% at week 13) in the AID group and by 0.3 percentage points (from 8.1±1.2% to 7.7±1.1%) in the control group (mean adjusted difference, -0.6 percentage points; 95% confidence interval [CI], -0.8 to -0.4; P<0.001). The mean percentage of time that patients were in the target glucose range of 70 to 180 mg per deciliter increased from 48±24% to 64±16% in the AID group and from 51±21% to 52±21% in the control group (mean difference, 14 percentage points; 95% CI, 11 to 17; P<0.001). All other multiplicity-controlled CGM outcomes reflective of hyperglycemia that were measured were significantly better in the AID group than in the control group. The frequency of CGM-measured hypoglycemia was low in both groups. A severe hypoglycemia event occurred in one patient in the AID group. In this 13-week, randomized, controlled trial involving adults with insulin-treated type 2 diabetes, AID was associated with a greater reduction in glycated hemoglobin levels than CGM alone. (Funded by Tandem Diabetes Care; 2IQP ClinicalTrials.gov number, NCT05785832.).Keywords
Funding Information
- Tandem Diabetes Care
This publication has 23 references indexed in Scilit:
- Automated Insulin Delivery in Adults With Type 2 DiabetesJAMA Network Open, 2025
- Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trialNature Medicine, 2023
- Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 DiabetesNew England Journal of Medicine, 2022
- Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trialNature Medicine, 2021
- Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal InsulinJAMA, 2021
- A Randomized Trial of Closed-Loop Control in Children with Type 1 DiabetesNew England Journal of Medicine, 2020
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 DiabetesNew England Journal of Medicine, 2019
- Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 DiabetesDiabetes Technology & Therapeutics, 2019
- Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 DiabetesDiabetes Technology & Therapeutics, 2017
- Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 DiabetesJAMA, 2016